- Home
- EPRX vs OFS Comparison
EPRX vs OFS Comparison
Compare EPRX & OFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPRX
- OFS
- Stock Information
- Founded
- EPRX 2011
- OFS 2001
- Country
- EPRX Canada
- OFS United States
- Employees
- EPRX N/A
- OFS N/A
- Industry
- EPRX
- OFS Finance/Investors Services
- Sector
- EPRX
- OFS Finance
- Exchange
- EPRX NYSE
- OFS Nasdaq
- Market Cap
- EPRX 111.1M
- OFS 110.3M
- IPO Year
- EPRX N/A
- OFS 2012
- Fundamental
- Price
- EPRX $3.85
- OFS $8.49
- Analyst Decision
- EPRX Strong Buy
- OFS
- Analyst Count
- EPRX 1
- OFS 0
- Target Price
- EPRX $9.00
- OFS N/A
- AVG Volume (30 Days)
- EPRX 8.8K
- OFS 58.6K
- Earning Date
- EPRX 05-07-2025
- OFS 05-01-2025
- Dividend Yield
- EPRX N/A
- OFS 16.27%
- EPS Growth
- EPRX N/A
- OFS N/A
- EPS
- EPRX N/A
- OFS 2.12
- Revenue
- EPRX N/A
- OFS $47,964,000.00
- Revenue This Year
- EPRX N/A
- OFS N/A
- Revenue Next Year
- EPRX N/A
- OFS N/A
- P/E Ratio
- EPRX N/A
- OFS $3.94
- Revenue Growth
- EPRX N/A
- OFS N/A
- 52 Week Low
- EPRX $2.20
- OFS $7.75
- 52 Week High
- EPRX $4.48
- OFS $10.04
- Technical
- Relative Strength Index (RSI)
- EPRX N/A
- OFS 49.51
- Support Level
- EPRX N/A
- OFS $8.20
- Resistance Level
- EPRX N/A
- OFS $8.66
- Average True Range (ATR)
- EPRX 0.00
- OFS 0.43
- MACD
- EPRX 0.00
- OFS -0.01
- Stochastic Oscillator
- EPRX 0.00
- OFS 47.02
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.